CVS Stock Analysis: CVS Health | NYSE

Healthcare Plans | NYSE, USA | Market Cap: 114.321m USD | 12M Return: 7.6% | US1266501006 | Charts, Fundamentals & Technical Analysis

Health Insurance, Pharmacy Benefits, Prescription Drugs, Consumer Wellness
Total Rating 46
Safety 61
Buy Signal -0.39
Health Care Services
Sub-Industry Rotation: +1.7
Market Cap: 114B
Avg Turnover: 895M
Risk 3d forecast
Volatility40.8%
VaR 5th Pctl6.59%
VaR vs Median-1.60%
Reward TTM
Sharpe Ratio0.27
Rel. Str. IBD29.1
Rel. Str. Peer Group18.3 pctl
Character TTM
Beta0.117
Beta Downside0.382
Hurst Exponent0.490
Choppyness63.0%
Drawdowns 3y
Max DD43.98%
CAGR/Max DD0.22
CAGR/Mean DD0.70
EPS (Earnings per Share) EPS (Earnings per Share) of CVS over the last years for every Quarter: "2021-09": 1.97, "2021-12": 1.98, "2022-03": 2.22, "2022-06": 2.4, "2022-09": 2.15, "2022-12": 1.99, "2023-03": 2.2, "2023-06": 2.21, "2023-09": 2.21, "2023-12": 2.12, "2024-03": 1.31, "2024-06": 1.83, "2024-09": 1.09, "2024-12": 1.19, "2025-03": 2.25, "2025-06": 1.81, "2025-09": 1.6, "2025-12": 1.09, "2026-03": 2.57, "2026-06": 2.58, "2026-09": 2.09,
EPS CAGR: 0.11%
EPS Trend: 0.7%
Last SUE: 1.44
Qual. Beats: 3
Revenue Revenue of CVS over the last years for every Quarter: 2021-09: 73794, 2021-12: 76604, 2022-03: 76826, 2022-06: 80636, 2022-09: 81159, 2022-12: 83846, 2023-03: 85278, 2023-06: 88921, 2023-09: 89764, 2023-12: 93813, 2024-03: 88437, 2024-06: 91234, 2024-09: 95428, 2024-12: 97710, 2025-03: 94588, 2025-06: 98915, 2025-09: 102871, 2025-12: 105693, 2026-03: 100426, 2026-06: 106096, 2026-09: 108399,
Rev. CAGR: 6.45%
Rev. Trend: 99.4%
Last SUE: 2.00
Qual. Beats: 3

Warnings

Below Avwap Earnings
Below Sma 200d

Tailwinds

Confidence

Seasonality 11.9 years of data, until 10/2026

Jan +0.2% 0
Feb -0.5% 0
Mar -2.0% 4
Apr -0.9% 4
May -3.3% 4
Jun +1.5% 28
Jul -0.1% 0
Aug +0.4% 0
Sep +0.8% 4
Oct +0.5% 0
Nov +4.7% 9
Dec -3.8% 0

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.

Description: CVS CVS Health

CVS Health Corporation is a U.S. healthcare company headquartered in Woonsocket, Rhode Island, founded in 1963 and publicly traded on the NYSE under the ticker CVS. It operates as an integrated healthcare enterprise spanning three core segments: Health Care Benefits (insurance products and related services such as medical, pharmacy, dental, behavioral health, Medicare Advantage, and Medicaid plans), Health Services (pharmacy benefit management, specialty and mail-order pharmacy, and clinical/administrative services), and Pharmacy & Consumer Wellness (retail pharmacy operations, OTC drug sales, and general merchandise). The companys customers include employers, individuals, government entities, health plans, unions, and other sponsors of health benefit programs. Originally named CVS Caremark Corporation, the company adopted its current name in September 2014.

CVS Health is classified within the Health Care sector, specifically the Health Care Services sub-industry, and is considered a large-cap stock. Its vertically integrated business model-combining a major PBM (Caremark), a large health insurer (Aetna, acquired in 2018), and one of the largest U.S. retail pharmacy chains-makes it a notable player in the managed care and pharmacy services space, a sector characterized by scale-driven bargaining power with drug manufacturers and providers.

Headlines to Watch Out For
  • Aetna Medicare Advantage medical costs trend above expectations
  • Caremark PBM margins face regulatory and legislative pressure on rebates
  • Retail pharmacy front-store sales pressured by Amazon and Walgreens competition
Piotroski VR-10 (Strict) 3.5
Net Income: 11.1b TTM > 0 and > 6% of Revenue
FCF/TA: 0.06 > 0.02 and ΔFCF/TA 3.57 > 1.0
NWC/Revenue: -3.26% < 20% (prev -3.95%; Δ 0.70% < -1%)
CFO/TA 0.07 > 3% & CFO 18.7b > Net Income 11.1b
Net Debt (75.0b) to EBITDA (19.7b): 3.81 < 3
Current Ratio: 0.85 > 1.5 & < 3
Outstanding Shares: last quarter (1.29b) vs 12m ago 1.73% < -2%
Gross Margin: 14.23% > 18% (prev 13.88%; Δ 0.35% > 0.5%)
Asset Turnover: 163.9% > 50% (prev 154.3%; Δ 9.51% > 0%)
Interest Coverage Ratio: 4.95 > 6 (EBIT TTM 15.2b / Interest Expense TTM 3.06b)
Altman Z'' 1.37
A: -0.05 (Total Current Assets 79.4b - Total Current Liabilities 93.1b) / Total Assets 258b
B: 0.26 (Retained Earnings 66.7b / Total Assets 258b)
C: 0.06 (EBIT TTM 15.2b / Avg Total Assets 257b)
D: 0.45 (Book Value of Equity 80.5b / Total Liabilities 177b)
Altman-Z'' = 1.37 = BB
Beneish M -3.09
DSRI: 0.90 (Receivables 42.1b/43.9b, Revenue 421b/394b)
GMI: 0.98 (GM 13.88% / 14.23%)
AQI: 1.00 (AQ_t 0.59 / AQ_t-1 0.59)
SGI: 1.07 (Revenue 421b / 394b)
TATA: -0.03 (NI 11.1b - CFO 18.7b) / TA 258b)
Beneish M = -3.09 (Cap -4..+1) = AA
What is the price of CVS shares?

As of November 19, 2026, the stock is trading at USD 81.35 with a total of 17,192,372 shares traded. Over the past week, the price has changed by -9.13%, over one month by -11.60%, over three months by -13.67% and over the past year by +7.58%.

Current recommended Stop Loss: 77.20 (which is 5.1% or 1.4 ATR below the current price).

Is CVS a buy, sell or hold?

CVS Health has received a consensus analysts rating of 4.54. Therefore, it is recommended to buy CVS.

  • StrongBuy: 18
  • Buy: 7
  • Hold: 3
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the CVS price?
Analysts Target Price 109.6 34.7%
CVS Health (CVS) - Fundamental Data Overview as of 16 November 2026
Market Cap USD = 114b (114b USD * 1.0 USD.USD)
P/E Trailing = 10.3775
P/E Forward = 10.5597
P/S = 0.2734
P/B = 1.4202
P/EG = 0.2178
Revenue TTM = 421b USD
EBIT TTM = 15.2b USD
EBITDA TTM = 19.7b USD
Long Term Debt = 57.2b USD (from longTermDebt, last quarter)
Short Term Debt = 5.38b USD (from shortTermDebt, last quarter)
Debt = 89.9b USD (from shortLongTermDebtTotal, last quarter) + Leases 14.6b
Net Debt = 75.0b USD (calculated: Debt 89.9b - CCE 14.9b)
Enterprise Value = 189b USD (114b + Debt 89.9b - CCE 14.9b)
Interest Coverage Ratio = 4.95 (Ebit TTM 15.2b / Interest Expense TTM 3.06b)
EV/FCF = 12.16x (Enterprise Value 189b / FCF TTM 15.6b)
FCF Yield = 8.22% (FCF TTM 15.6b / Enterprise Value 189b)
FCF Margin = 3.70% (FCF TTM 15.6b / Revenue TTM 421b)
Net Margin = 2.63% (Net Income TTM 11.1b / Revenue TTM 421b)
Gross Margin = 14.23% ((Revenue TTM 421b - Cost of Revenue TTM 361b) / Revenue TTM)
Gross Margin QoQ = 13.74% (prev 14.84%)
Tobins Q-Ratio = 0.73 (Enterprise Value 189b / Total Assets 258b)
Interest Expense / Debt = 3.41% (Interest Expense 3.06b / Debt 89.9b)
Taxrate = 8.96% (1.09b / 12.1b)
NOPAT = 13.8b (EBIT 15.2b * (1 - 8.96%))
Current Ratio = 0.85 (Total Current Assets 79.4b / Total Current Liabilities 93.1b)
Debt / Equity = 1.12 (Debt 89.9b / totalStockholderEquity, last quarter 80.5b)
Debt / EBITDA = 3.81 (Net Debt 75.0b / EBITDA 19.7b)
Debt / FCF = 4.82 (Net Debt 75.0b / FCF TTM 15.6b)
Total Stockholder Equity = 78.2b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.31% (Net Income 11.1b / Total Assets 258b)
RoE = 14.13% (Net Income TTM 11.1b / Total Stockholder Equity 78.2b)
RoCE = 11.21% (EBIT 15.2b / Capital Employed (Equity 78.2b + L.T.Debt 57.2b))
RoIC = 8.89% (NOPAT 13.8b / Invested Capital 155b)
WACC = 4.75% (E(114b)/V(204b) * Re(6.04%) + D(89.9b)/V(204b) * Rd(3.41%) * (1-Tc(0.09)))
Discount Rate = 6.04% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 97.57 | Cagr: 1.12%
[DCF] Terminal Value 77.97% ; FCFF base≈11.9b ; Y1≈13.6b ; Y5≈20.0b
[DCF] Fair Price = 176.6 (EV 301b - Net Debt 75.0b = Equity 226b / Shares 1.28b; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 0.73 | EPS CAGR: 0.11% | SUE: 1.44 | # QB: 3
Revenue Correlation: 99.39 | Revenue CAGR: 6.45% | SUE: 2.00 | # QB: 3
EPS current Quarter (2027-03-31): EPS=2.74 | Chg30d=+2.17% | Revisions=+10% | Analysts=12
EPS current Year (2026-12-31): EPS=8.29 | Chg30d=+3.02% | Revisions=+81% | GrowthEPS=+22.8% | GrowthRev=+4.9%
EPS next Year (2027-12-31): EPS=8.68 | Chg30d=+1.74% | Revisions=+61% | GrowthEPS=+4.8% | GrowthRev=+2.1%
[Analyst] Revisions Ratio: +66% (up=30, down=5)